CopyMark Law Group
4.9/5
Drawing for NEPHROCHECK

USPTO serial 88489818

NEPHROCHECK

Reviewed by CopyMark Law Group

Reg. 5971753Status 702Registered
Filing date
Status date
Registration date
Jan 28, 2020
Examiner
KHAN, AHSEN M
Law office
Historical data usage

What this means

Status 702 means the registration is active, Section 8 was accepted, and a Section 15 declaration of incontestability was also accepted. Incontestability strengthens your rights by limiting certain challenges after five years of continuous use. Continue use in commerce and plan for the 10-year Section 8 and 9 renewal.

Status 702: Status 702 means the registration is active, Section 8 was accepted, and a Section 15 declaration of incontestability was also accepted. Incontestability strengthens your rights by limiting certain challenges after five years of continuous use.

Need help with NEPHROCHECK?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Trademark Monitoring
(312) 319-4460
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Start a new application
(312) 319-4460

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Martin M. Zoltick

Martin M. Zoltick Rothwell, Figg, Ernst & Manbeck, PC901 New York Avenue, NWSuite 900 EastWashington, DC 20001

Goods and services

ClassDescriptionStatusFirst use
005Chemical reagents and laboratory reagents for medical, medicinal pharmaceutical and veterinary use, namely, for use in the preparation of in vitro diagnostic kits; diagnostic preparations for medical, medicinal pharmaceutical and veterinary use in the field of in vitro diagnostics; immunoassay kits consisting primarily of immunological reagents for medical diagnostic use; medical diagnostic test strips for immunological analysesACTIVEJun 10, 2012
010Medical instruments and apparatus used to detect markers for medical use in the field of in vitro diagnostics; medical and veterinary apparatus and instruments for diagnostic detection of biological molecules; Laboratory instruments and apparatus, namely, test kits comprised primarily of medical diagnostic apparatus used to detect markers, test strips, test cassettes, pipettes, test tubes, vials, and laboratory cards for diagnostic indicator purposes for immunological analysis; immunology analyzers for in vitro diagnostic useACTIVEJun 10, 2012

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
May 1, 2026TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
May 1, 2026ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
May 1, 2026REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
May 1, 2026CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
May 1, 2026COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
Apr 20, 2026NA85NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED—
Apr 20, 2026C15AREGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.—
Apr 20, 2026APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Jan 27, 2026E815TEAS SECTION 8 & 15 RECEIVED—
Jun 11, 2025ASGNAUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP—
Jan 28, 2025REM1COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED—
Jan 28, 2020R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Nov 12, 2019NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Nov 12, 2019PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Oct 23, 2019NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Oct 3, 2019ALIEASSIGNED TO LIE—
Sep 26, 2019CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Sep 25, 2019TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Sep 25, 2019CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Sep 25, 2019TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Sep 19, 2019GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Sep 19, 2019GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Sep 19, 2019CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Sep 17, 2019DOCKASSIGNED TO EXAMINER—
Jul 6, 2019NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jun 29, 2019NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance